polo like kinase 2 | Polo-like kinase (PLK) family | IUPHAR/BPS Guide to PHARMACOLOGY

Top ▲

polo like kinase 2

Target not currently curated in GtoImmuPdb

Target id: 2169

Nomenclature: polo like kinase 2

Abbreviated Name: PLK2

Family: Polo-like kinase (PLK) family

Annotation status:  image of an orange circle Annotated and awaiting review. Please contact us if you can help with reviewing.  » Email us

Gene and Protein Information
Species TM AA Chromosomal Location Gene Symbol Gene Name Reference
Human - 685 5q12.1-q13.2 PLK2 polo like kinase 2
Mouse - 682 13 D2.1 Plk2 polo like kinase 2
Rat - 682 2 q14 Plk2 polo-like kinase 2
Previous and Unofficial Names
polo-like kinase 1 | serine/threonine-protein kinase SNK | serum-inducible kinase | polo-like kinase 2
Database Links
BRENDA
CATH/Gene3D
ChEMBL Target
Ensembl Gene
Entrez Gene
Human Protein Atlas
KEGG Enzyme
KEGG Gene
OMIM
RefSeq Nucleotide
RefSeq Protein
SynPHARM
UniProtKB
Wikipedia
Enzyme Reaction
EC Number: 2.7.11.21

Download all structure-activity data for this target as a CSV file

Inhibitors
Key to terms and symbols View all chemical structures Click column headers to sort
Ligand Sp. Action Value Parameter Reference
BI-2536 Hs Inhibition 8.5 pIC50 5
pIC50 8.5 (IC50 3.5x10-9 M) [5]
NMS-P937 Hs Inhibition <5.0 pIC50 2
pIC50 <5.0 (IC50 >1x10-5 M) [2]
DiscoveRx KINOMEscan® screen
A screen of 72 inhibitors against 456 human kinases. Quantitative data were derived using DiscoveRx KINOMEscan® platform.
http://www.discoverx.com/services/drug-discovery-development-services/kinase-profiling/kinomescan
Reference: 3,6

Key to terms and symbols Click column headers to sort
Target used in screen: PLK2
Ligand Sp. Type Action Value Parameter
BI-2536 Hs Inhibitor Inhibition 9.1 pKd
tamatinib Hs Inhibitor Inhibition 7.5 pKd
staurosporine Hs Inhibitor Inhibition 6.7 pKd
lestaurtinib Hs Inhibitor Inhibition 6.5 pKd
GSK-461364A Hs Inhibitor Inhibition 6.3 pKd
dovitinib Hs Inhibitor Inhibition 6.2 pKd
bosutinib Hs Inhibitor Inhibition 6.0 pKd
NVP-TAE684 Hs Inhibitor Inhibition 5.9 pKd
PP-242 Hs Inhibitor Inhibition 5.8 pKd
ruxolitinib Hs Inhibitor Inhibition 5.8 pKd
Displaying the top 10 most potent ligands  View all ligands in screen »
EMD Millipore KinaseProfilerTM screen/Reaction Biology Kinase HotspotSM screen
A screen profiling 158 kinase inhibitors (Calbiochem Protein Kinase Inhibitor Library I and II, catalogue numbers 539744 and 539745) for their inhibitory activity at 1µM and 10µM against 234 human recombinant kinases using the EMD Millipore KinaseProfilerTM service.

A screen profiling the inhibitory activity of 178 commercially available kinase inhibitors at 0.5µM against a panel of 300 recombinant protein kinases using the Reaction Biology Corporation Kinase HotspotSM platform.

http://www.millipore.com/techpublications/tech1/pf3036
http://www.reactionbiology.com/webapps/main/pages/kinase.aspx


Reference: 1,4

Key to terms and symbols Click column headers to sort
Target used in screen: Snk/PLK2
Ligand Sp. Type Action % Activity remaining at 0.5µM % Activity remaining at 1µM % Activity remaining at 10µM
PDK1/Akt/Flt dual pathway inhibitor Hs Inhibitor Inhibition 37.3 73.0 34.0
casein kinase II inhibitor III Hs Inhibitor Inhibition 51.5 39.0 25.0
wortmannin Hs Inhibitor Inhibition 51.6
SB 218078 Hs Inhibitor Inhibition 62.4 105.0 80.0
isogranulatimide Hs Inhibitor Inhibition 63.8 38.0 38.0
PKR inhibitor Hs Inhibitor Inhibition 78.7 49.0 17.0
fascaplysin Hs Inhibitor Inhibition 79.9 95.0 101.0
aloisine A Hs Inhibitor Inhibition 83.9 100.0 86.0
KU-55933 Hs Inhibitor Inhibition 84.6 93.0 96.0
Cdk1/2 inhibitor III Hs Inhibitor Inhibition 88.5 71.0 26.0
Displaying the top 10 most potent ligands  View all ligands in screen »

References

Show »

1. Anastassiadis T, Deacon SW, Devarajan K, Ma H, Peterson JR. (2011) Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity. Nat. Biotechnol., 29 (11): 1039-45. [PMID:22037377]

2. Beria I, Bossi RT, Brasca MG, Caruso M, Ceccarelli W, Fachin G, Fasolini M, Forte B, Fiorentini F, Pesenti E et al.. (2011) NMS-P937, a 4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline derivative as potent and selective Polo-like kinase 1 inhibitor. Bioorg. Med. Chem. Lett., 21 (10): 2969-74. [PMID:21470862]

3. Davis MI, Hunt JP, Herrgard S, Ciceri P, Wodicka LM, Pallares G, Hocker M, Treiber DK, Zarrinkar PP. (2011) Comprehensive analysis of kinase inhibitor selectivity. Nat. Biotechnol., 29 (11): 1046-51. [PMID:22037378]

4. Gao Y, Davies SP, Augustin M, Woodward A, Patel UA, Kovelman R, Harvey KJ. (2013) A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. Biochem. J., 451 (2): 313-28. [PMID:23398362]

5. Steegmaier M, Hoffmann M, Baum A, Lénárt P, Petronczki M, Krssák M, Gürtler U, Garin-Chesa P, Lieb S, Quant J et al.. (2007) BI 2536, a potent and selective inhibitor of polo-like kinase 1, inhibits tumor growth in vivo. Curr. Biol., 17 (4): 316-22. [PMID:17291758]

6. Wodicka LM, Ciceri P, Davis MI, Hunt JP, Floyd M, Salerno S, Hua XH, Ford JM, Armstrong RC, Zarrinkar PP et al.. (2010) Activation state-dependent binding of small molecule kinase inhibitors: structural insights from biochemistry. Chem. Biol., 17 (11): 1241-9. [PMID:21095574]

How to cite this page

Polo-like kinase (PLK) family: polo like kinase 2. Last modified on 29/01/2016. Accessed on 23/08/2019. IUPHAR/BPS Guide to PHARMACOLOGY, http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2169.